Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Hematological Tumor - Pipeline Review, H1 2013

Enquire | Email | Print

ISBN: GMDHC3696IDB
Published Date: Jun, 2013
Format: PDF
No of Pages: 265
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Summary

'Hematological Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hematological Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematological Tumor. Hematological Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hematological Tumor.
- A review of the Hematological Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hematological Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hematological Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hematological Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.




Table of Contents
Table of Contents 2
Introduction 5
Hematological Tumor Overview 6
Therapeutics Development 7
Hematological Tumor Therapeutics under Development by Companies 9
Hematological Tumor Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 15
Early Clinical Stage Products 16
Discovery and Pre-Clinical Stage Products 17
Hematological Tumor Therapeutics – Products under Development by Companies 18
Hematological Tumor Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Hematological Tumor Therapeutics Development 25
Hematological Tumor – Therapeutics Assessment 83
Drug Profiles 88
Hematological Tumor Therapeutics – Drug Profile Updates 206
Hematological Tumor Therapeutics – Discontinued Products 244
Hematological Tumor Therapeutics - Dormant Products 245
Hematological Tumor – Product Development Milestones 248
Appendix 254

List of Tables
Number of Products Under Development for Hematological Tumor, H1 2013 17
Products under Development for Hematological Tumor – Comparative Analysis, H1 2013 18
Number of Products under Development by Companies, H1 2013 20
Number of Products under Development by Companies, H1 2013 (Contd..1) 21
Number of Products under Development by Companies, H1 2013 (Contd..2) 22
Number of Products under Development by Companies, H1 2013 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2013 24
Comparative Analysis by Mid Clinical Stage Development, H1 2013 25
Comparative Analysis by Early Clinical Stage Development, H1 2013 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 27
Products under Development by Companies, H1 2013 28
Products under Development by Companies, H1 2013 (Contd..1) 29
Products under Development by Companies, H1 2013 (Contd..2) 30
Products under Development by Companies, H1 2013 (Contd..3) 31
Products under Development by Companies, H1 2013 (Contd..4) 32
Products under Development by Companies, H1 2013 (Contd..5) 33
Products under Investigation by Universities/Institutes, H1 2013 34
F. Hoffmann-La Roche Ltd., H1 2013 35
Sanofi-Aventis, H1 2013 36
AstraZeneca PLC, H1 2013 37
Eli Lilly and Company, H1 2013 38
GlaxoSmithKline plc, H1 2013 39
MedImmune LLC, H1 2013 40
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 41
Infinity Pharmaceuticals, Inc., H1 2013 43
Symphogen A/S, H1 2013 44
Piramal Healthcare Limited, H1 2013 45
Millennium Pharmaceuticals, Inc., H1 2013 46
Novartis AG, H1 2013 47
Ono Pharmaceutical Co., Ltd., H1 2013 48
Pfizer Inc., H1 2013 49
SuperGen, Inc., H1 2013 50
Taiho Pharmaceutical Co., Ltd., H1 2013 51
Onyx Pharmaceuticals, Inc., H1 2013 52
4SC AG, H1 2013 55
EntreMed, Inc., H1 2013 56
Idera Pharmaceuticals, Inc., H1 2013 57
Basilea Pharmaceutica Ltd., H1 2013 58
Patrys Limited, H1 2013 59
Curis, Inc., H1 2013 60
ARQULE, INC, H1 2013 61
CrystalGenomics, Inc., H1 2013 64
Algeta ASA, H1 2013 65
Cellerant Therapeutics, Inc., H1 2013 66
Oryzon, H1 2013 67
Pieris AG, H1 2013 68
Nerviano Medical Sciences S.r.l., H1 2013 69
Aegera Therapeutics Inc., H1 2013 70
Altor BioScience Corporation, H1 2013 71
MacroGenics, Inc., H1 2013 72
Arno Therapeutics, Inc., H1 2013 73
ACT Biotech, Inc., H1 2013 74
Spirogen Ltd., H1 2013 75
Constellation Pharmaceuticals, Inc., H1 2013 76
GENETIX Pharmaceuticals, Inc., H1 2013 77
Stemline Therapeutics, Inc., H1 2013 78
AndroScience Corporation, H1 2013 79
NOXXON Pharma AG, H1 2013 80
Esperance Pharmaceuticals, Inc., H1 2013 81
Oncolys BioPharma Inc., H1 2013 82
PharmaMar, S.A., H1 2013 83
AmpliMed Corporation, H1 2013 84
Aprea AB., H1 2013 85
TRACON Pharmaceuticals, Inc., H1 2013 86
Dynamix Pharmaceuticals Ltd., H1 2013 87
EpiZyme, Inc., H1 2013 88
Vaxiion Therapeutics, Inc., H1 2013 89
IkerChem S.L., H1 2013 90
Immunovative Therapies, Ltd., H1 2013 91
BerGenBio AS, H1 2013 92
Assessment by Monotherapy Products, H1 2013 93
Assessment by Stage and Route of Administration, H1 2013 95
Assessment by Stage and Molecule Type, H1 2013 97
Hematological Tumor Therapeutics – Drug Profile Updates 216
Hematological Tumor Therapeutics – Discontinued Products 254
Hematological Tumor Therapeutics – Dormant Products 255
Hematological Tumor Therapeutics – Dormant Products (Contd..1) 256
Hematological Tumor Therapeutics – Dormant Products (Contd..2) 257

List of Figures
Number of Products under Development for Hematological Tumor, H1 2013 17
Products under Development for Hematological Tumor – Comparative Analysis, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 24
Mid Clinical Stage Products, H1 2013 25
Early Clinical Stage Products, H1 2013 26
Discovery and Pre-Clinical Stage Products, H1 2013 27
Assessment by Monotherapy Products, H1 2013 93
Assessment by Route of Administration, H1 2013 94
Assessment by Stage and Route of Administration, H1 2013 95
Assessment by Molecule Type, H1 2013 96
Assessment by Stage and Molecule Type, H1 2013 97




Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 361173, price: INR 121808, Global Markets Direct

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online